Literature DB >> 27818010

The gross motor function measure is valid for Fukuyama congenital muscular dystrophy.

Takatoshi Sato1, Michiru Adachi2, Kaho Nakamura2, Masaya Zushi2, Keisuke Goto2, Terumi Murakami1, Kumiko Ishiguro1, Minobu Shichiji1, Kayoko Saito3, Tetsuo Ikai4, Makiko Osawa1, Izumi Kondo5, Satoru Nagata1, Keiko Ishigaki6.   

Abstract

Fukuyama congenital muscular dystrophy (FCMD) is the second most common muscular dystrophy in Japan. FCMD is an autosomal recessive disorder caused by mutations in the fukutin gene. The main features of FCMD are a combination of infantile-onset hypotonia, generalized muscle weakness, eye abnormalities, and mental retardation associated with cortical migration defects, and most patients are never able to walk. To date, the development of a quantitative motor scale for FMCD has been difficult due to the moderate-to-severe intellectual impairment that accompanies FCMD. Gross motor function measure (GMFM), originally developed as a quantitative motor scale for cerebral palsy, can precisely and quantitatively assess motor function without complicated instructions, and was recently reported to be useful in the assessment of Down syndrome and spinal muscular atrophy. To confirm the validity of GMFM for the assessment of FCMD, 41 FCMD patients (age range: 0.6-24.4 years) were recruited for this study. The GMFM scores correlated significantly with those of two previously used motor scales, and the time-dependent change in GMFM scores was consistent with the natural course of FCMD. The inter-rater reliability, based on determinations made by four physiotherapists blinded to each other's assessment results, was excellent. We concluded GMFM to be a useful and valid measure of motor function in FCMD patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fukuyama congenital muscular dystrophy; Gross motor function measure; Intellectual involvement

Mesh:

Year:  2016        PMID: 27818010     DOI: 10.1016/j.nmd.2016.09.014

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Daily Outpatient Physical Therapy for a Toddler With a Neurodegenerative Disease: A Case Report.

Authors:  Rachel Bican; Rachel Ferrante; Sarah Hendershot; Michelle Byars; Warren Lo; Jill C Heathcock
Journal:  Pediatr Phys Ther       Date:  2022-04-01       Impact factor: 1.452

2.  Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.

Authors:  J Schaefers; L J van der Giessen; C Klees; E H Jacobs; S Sieverdink; M H G Dremmen; J K H Spoor; A T van der Ploeg; J M P van den Hout; H H Huidekoper
Journal:  Orphanet J Rare Dis       Date:  2021-05-14       Impact factor: 4.123

3.  Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report.

Authors:  Kondakova Olga Borisovna; Krasnenko Anna Yurievna; Tsukanov Kirill Yurievich; Klimchuk Olesya Igorevna; Korostin Dmitriy Olegovich; Davidova Anna Igorevna; Batysheva Tatyana Timofeevna; Zhurkova Natalia Vyacheslavovna; Surkova Ekaterina Ivanovna; Shatalov Peter Alekseevich; Ilinsky Valery Vladimirovich
Journal:  BMC Pediatr       Date:  2019-04-08       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.